| Primary |
| Stem Cell Transplant |
82.5% |
| Drug Use For Unknown Indication |
4.9% |
| Neuroblastoma |
3.1% |
| Prophylaxis Against Graft Versus Host Disease |
3.1% |
| Bone Marrow Conditioning Regimen |
2.2% |
| Graft Versus Host Disease |
1.3% |
| Ill-defined Disorder |
0.9% |
| Acute Myeloid Leukaemia |
0.4% |
| B-cell Type Acute Leukaemia |
0.4% |
| Chronic Myelomonocytic Leukaemia |
0.4% |
| Hyperbilirubinaemia |
0.4% |
|
| Vomiting |
21.9% |
| Stomatitis |
18.8% |
| Venoocclusive Liver Disease |
14.1% |
| Weight Increased |
6.3% |
| Thrombotic Microangiopathy |
5.5% |
| Graft Versus Host Disease |
3.9% |
| Stem Cell Transplant |
3.9% |
| Sepsis |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Pleural Effusion |
2.3% |
| Staphylococcal Sepsis |
2.3% |
| Viraemia |
2.3% |
| Lymphoproliferative Disorder |
1.6% |
| Pneumonia Staphylococcal |
1.6% |
| Renal Impairment |
1.6% |
| Respiratory Distress |
1.6% |
| Sarcoidosis |
1.6% |
| Shock |
1.6% |
| Streptococcal Sepsis |
1.6% |
| Thrombotic Thrombocytopenic Purpura |
1.6% |
|
| Secondary |
| Acute Myeloid Leukaemia |
35.0% |
| Stem Cell Transplant |
16.5% |
| Bone Marrow Conditioning Regimen |
15.5% |
| Graft Versus Host Disease |
5.5% |
| Acute Leukaemia |
5.0% |
| Myeloid Leukaemia |
4.5% |
| Haematological Malignancy |
3.0% |
| Leukaemia |
3.0% |
| Adrenoleukodystrophy |
2.0% |
| Chronic Lymphocytic Leukaemia |
2.0% |
| Medulloblastoma |
1.5% |
| Transplant |
1.5% |
| Acute Lymphocytic Leukaemia |
1.0% |
| Drug Use For Unknown Indication |
1.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.0% |
| Acute Myeloid Leukaemia Recurrent |
0.5% |
| Cord Blood Transplant Therapy |
0.5% |
| Myelodysplastic Syndrome |
0.5% |
| T-cell Depletion |
0.5% |
|
| Weight Increased |
23.6% |
| Venoocclusive Liver Disease |
14.5% |
| Oesophagitis |
5.5% |
| Unresponsive To Stimuli |
5.5% |
| Venoocclusive Disease |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Graft Versus Host Disease |
3.6% |
| Infection |
3.6% |
| Platelet Count Decreased |
3.6% |
| Renal Impairment |
3.6% |
| Stem Cell Transplant |
3.6% |
| Upper Respiratory Tract Infection |
3.6% |
| Vomiting |
3.6% |
| Weight Decreased |
3.6% |
| Acute Graft Versus Host Disease |
1.8% |
| Acute Lymphocytic Leukaemia Recurrent |
1.8% |
| Cytomegalovirus Viraemia |
1.8% |
| Dizziness Postural |
1.8% |
| Epstein-barr Virus Infection |
1.8% |
| Haemorrhage |
1.8% |
|
| Concomitant |
| Stem Cell Transplant |
31.3% |
| Bone Marrow Conditioning Regimen |
13.5% |
| Bone Marrow Transplant |
10.4% |
| Chemotherapy |
9.4% |
| Prophylaxis Against Graft Versus Host Disease |
8.3% |
| Graft Versus Host Disease |
5.2% |
| Prophylaxis |
5.2% |
| Haematopoietic Stem Cell Mobilisation |
3.1% |
| Cord Blood Transplant Therapy |
2.1% |
| Allogenic Bone Marrow Transplantation Therapy |
1.0% |
| Antifungal Prophylaxis |
1.0% |
| Chediak-higashi Syndrome |
1.0% |
| Chronic Myeloid Leukaemia |
1.0% |
| Combined Immunodeficiency |
1.0% |
| Confusional State |
1.0% |
| Essential Thrombocythaemia |
1.0% |
| Infection Prophylaxis |
1.0% |
| Mucopolysaccharidosis |
1.0% |
| Mucopolysaccharidosis I |
1.0% |
| Non-hodgkin's Lymphoma |
1.0% |
|
| Thrombotic Microangiopathy |
20.4% |
| Pancytopenia |
7.4% |
| Pseudomonal Sepsis |
7.4% |
| Pyrexia |
5.6% |
| Renal Failure |
5.6% |
| Stem Cell Transplant |
5.6% |
| Upper Gastrointestinal Haemorrhage |
5.6% |
| Delayed Engraftment |
3.7% |
| Engraft Failure |
3.7% |
| Epstein-barr Virus Infection |
3.7% |
| Headache |
3.7% |
| Infection |
3.7% |
| Multi-organ Failure |
3.7% |
| Pneumocystis Jiroveci Pneumonia |
3.7% |
| Sepsis |
3.7% |
| Septic Shock |
3.7% |
| Serum Ferritin Increased |
3.7% |
| Death |
1.9% |
| Encephalitis Herpes |
1.9% |
| Hypoxia |
1.9% |
|
